Section Arrow
Quote
EPRX.NASDAQ
- Eupraxia Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/16 04:41 EST
Regular Hours
Last
 6.56
+0.22 (+3.47%)
Day High 
7.0994 
Prev. Close
6.34 
1-M High
6.74 
Volume 
269.62K 
Bid
6.56
Ask
6.64
Day Low
6.1501 
Open
6.41 
1-M Low
5.25 
Market Cap 
321.11M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.95 
20-SMA 5.76 
50-SMA 5.77 
52-W High 7.19 
52-W Low 2.6801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.88/-0.97
Enterprise Value
321.11M
Balance Sheet
Book Value Per Share
1.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 04:41 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.